Hamptons Homebuildi...
Health Care: Drugs
Discovery Laboratories Inc. (DSCO: NASDAQ)
$1.60 -0.03 | -1.84%
05/24/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.60 |
| 52 Week High | 3.51 |
| 52 Week Low | 1.50 |
| Avg. Daily Vol. (Mil) | 0.38 |
| Beta (3 year) | 1.85 |
| Share Related Items | |
| Mkt Cap (Mil) | 85.22 |
| Shares Out (Mil) | 53.26 |
| Float (Mil) | 36.97 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 2.00 |
| Current Ratio | 2.10 |
| LT Debt/ Equity | 0.66 |
| Total Debt / Equity | 0.66 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 319.19 |
| Price/Book | 9.01 |
| Price/Cash Flow | -1.70 |
| Per Share Data | |
| Earnings | -0.91 |
| Sales | 0.01 |
| Book Value | 0.18 |
| Cash Flow | -0.92 |
| Business Summary | |
|---|---|
| Discovery Laboratories, Inc. is engaged in the development of Surfactant Replacement Therapies (SRT) to treat respiratory disorders and diseases for which there frequently are few or no approved therapies. | |
| General Information | |
| 2600 Kelly Road
Suite 100 Warrington, PA 18976-3622 |
|
| www.discoverylabs.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 119 | |
| CEO: John G. Cooper | |
| Short Interest | |
| Current Month (Mil) | 3.83 |
| Previous Month (Mil) | 3.72 |
| Short Interest Ratio (Days) | 10.70 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -171.30 |
| Return on Investments | -318.00 |
| Profitability | |
| Gross Margin | n.a. |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with DSCO
- Portfolio NameUser Type
- ContributorStocks Under-$10 Setting Up...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserKJP Spring Break
- ContributorStocks Under-$10 Setting Up...
- UserSmall Cap Stocks
- Userjet189 Portfolio 1
- Uservolume spike
- Usermoon_in_mood Portfolio 1
- UserDtech Portfolio 1
Latest DSCO Headlines from TheStreet
- 5 Stocks Under $10 Set to Explode 02.14.13 | 01:02 pm
- Discovery Labs Receives New US Patent For Pulmonary Surfactant Formulations 01.17.13 | 07:01 am
- Shorting Alexza Pharma On FDA's Adasuve Approval 12.19.12 | 07:12 am
- Discovery Labs To Present At The Stifel Nicolaus Healthcare Conference 2012 09.04.12 | 07:09 am
- 8 Stocks Under $10 Surging Higher 08.28.12 | 02:08 pm
- 7 Stocks Under $10 With Relative Strength 07.06.12 | 02:07 pm
- 5 Stocks Under $10 Poised for Upside 04.27.12 | 11:04 am
- For Biotech Takeovers, Timing is Key 04.04.12 | 06:04 am
- For Biotech, 'Fail' is Making a Big Comeback 03.12.12 | 08:03 am
- Biotech Stock Mailbag: Oncothyreon, Amag, Keryx Hate Mail 03.09.12 | 05:03 am
Press Releases for DSCO
- Discovery Labs Receives FDA Recommendations And Request For Clarification Regarding Recently-Submitted SURFAXIN® (lucinactant) Updated Product Specifications - PR Newswire 04.15.13 | 07:04 am
- Discovery Labs Announces Newly-Released SURFAXIN® (lucinactant) Publications - PR Newswire 03.29.13 | 07:03 am
- Discovery Labs To Report Fourth Quarter 2012 Results And Hold Conference Call On Wednesday, March 13, 2013 - PR Newswire 03.06.13 | 04:03 pm
- Discovery Labs Receives $30 Million Funding Commitment From Deerfield Management - PR Newswire 02.13.13 | 04:02 pm
- Discovery Labs Announces Changes To Board Of Directors And Appoints A New Chief Executive Officer - PR Newswire 01.04.13 | 08:01 am
- Discovery Labs Initiates Launch Of AFECTAIR® - PR Newswire 01.03.13 | 07:01 am
- New Pharmacoeconomic Analysis Shows Lower Rate Of Reintubation Observed With SURFAXIN® Treatment May Reduce Hospital Costs Associated With Bronchopulmonary Dysplasia - PR Newswire 12.04.12 | 07:12 am
- Discovery Labs Presents New SURFAXIN® And AFECTAIR® Data At 2012 Hot Topics In Neonatology Annual Meeting - PR Newswire 11.28.12 | 07:11 am
- Discovery Labs Appoints John R. Leone To Board Of Directors - PR Newswire 11.14.12 | 07:11 am
- Discovery Labs Provides Commercial Update For SURFAXIN® And AFECTAIR® - PR Newswire 10.24.12 | 07:10 am
Partner Headlines for DSCO
- Time To Take Another Look At The Biotechnology Sector - Seeking Alpha 04.09.12 | 09:04 am
- Bio-Pharma Drug Approval Watch List: Final Results Plus One To Watch - Seeking Alpha 03.30.12 | 09:03 am
- Discovery Labs Down 17% After Public Offering Announcement - Benzinga 03.16.12 | 09:03 am
- Company News for March 8, 2012 - Corporate Summary - Zacks 03.08.12 | 10:03 am
- Discovery Labs Up 33% After Surfaxin Approved by the FDA - Benzinga 03.07.12 | 09:03 am
- Discovery Labs Announces FDA Approval of SURFAXIN for Prevention of Respiratory Distress Syndrome - Benzinga 03.06.12 | 04:03 pm
- Zacks #1 Rank Additions for Tuesday - Tale of the Tape - Zacks 11.15.11 | 09:11 am
- UPDATE 1-Discovery Labs' cystic fibrosis drug gets orphan status - Reuters 11.01.10 | 08:11 am
- UPDATE 1-Discovery Labs lung drug disappoints in mid-stage trial - Reuters 06.09.10 | 08:06 am
- FDA, Clinical Trial News: Discovery Labs, Hospira, Javelin Pharma - Seeking Alpha 05.20.10 | 06:05 am
